GlassScriptPhysician profile
Hamid Emamekhoo
NPI 1053602342
$23,113.60
in general payments reported to CMS, 2019-2025
16 companies · $336 in 2025
The $336 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,124 · 2020: $5,723 · 2021: $1,380 · 2022: $4,950 · 2023: $1,512 · 2024: $4,088 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,908 · Food and Beverage: $918 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,907.50 |
| Food and Beverage | $917.61 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $111.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $7,476.90 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $4,981.55 | 2019-2024 | |
| Seagen INC. | $3,220.00 | 2021-2022 | |
| Janssen Biotech, INC. | $2,401.00 | 2019-2023 | |
| Aveo Pharmaceuticals, INC. | $2,234.87 | 2022-2024 | |
| Eisai INC. | $1,702.07 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $511.52 | 2024 | Imfinzi |
| Pfizer INC. | $282.46 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $149.54 | 2023 | Epkinly, Imbruvica |
| Cardinal Health 110 LLC | $100.00 | 2020 | |
| Sumitomo Pharma America, INC. | $53.69 | 2025 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hamid Emamekhoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.